Drug Trial Radar · NCT07502560
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
33,609
Planned (sponsor's estimate)
Start
Mar 31, 2026
Primary completion
Apr 1, 2030
Study completion Mar 31, 2037
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Finnish Vaccine Research;; Dr Arto Palmu
- First posted
- Mar 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 76 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.
Conditions
- Herpes Zoster
Interventions
Recombinant zoster vaccineBiological
Recombinant zoster vaccine administered intramuscularly, one dose at Visit 1 (Day 1) and one dose at Visit 2 (between 2 and 6 months after the first dose), according to the approved recombinant zoster vaccine dosing schedule.
PlaceboDrug
Placebo administered intramuscularly, one dose at Visit 1 (Day 1) and one dose at Visit 2 (between 2 and 6 months after the first dose).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hazard ratio of incident dementia diagnosisTime frame: From first dose of study intervention (Day 1) until the date of first dementia diagnosis, death, loss to follow-up, or end of data availability, whichever occurs first, assessed up to 10 years
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Espoo, Finland · Recruiting
GSK Investigational Site
Helsinki, Finland · Recruiting
GSK Investigational Site
Jarvenpaa, Finland · Recruiting
GSK Investigational Site
Kokkola, Finland · Recruiting
GSK Investigational Site
Oulu, Finland · Recruiting
GSK Investigational Site
Seinäjoki, Finland · Recruiting
GSK Investigational Site
Tampere, Finland · Recruiting
GSK Investigational Site
Turku, Finland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.